MTOR and renal cell carcinoma: Mammalian target of rapamycin (mTOR) is inhibited by the tuberous sclerosis (TSC) complex, which, in turn, is inhibited by AKT and patients with TSC mutations have an increased incidence of RCC (Al-Saleem et al, 1998).